Abstract
The reported neuropsychological effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD) are inconsistent. The assumed relationships between these neuropsychological effects and clinical efficacy have not been substantiated. We therefore investigated the effects of chronic MPH administration on neuropsychological functioning. We conducted a 12-week, placebo-controlled, double-blinded, randomized, crossover trial (MPH .3 and .6 mg/kg/dose and placebo). Participants were 75 boys aged 7-15 years with ADHD. Neuropsychological performance was assessed with tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and a GoNoGo task. Chronic MPH improved performance (p < .001) on aspects of the GoNoGo task (p < .02) and on three CANTAB tasks which together contributed to a "recognition memory" component identified through principal components analysis (delayed matching to sample [DMtS], pattern and spatial recognition). There were no effects on other, high or low "executive demand" tasks (p > .05). GoNoGo performance improvements were the only neuropsychopharmacological changes associated with clinical response. Poor performance on the DMtS task was the sole baseline neuropsychological predictor of clinical response. Chronic MPH predominantly enhanced neuropsychological functioning on "recognition memory" component tasks with modest "executive" demands. Neuropsychological measures offer only modest contributions to the prediction of clinical responses to MPH in ADHD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call